$OTLC
Oncotelic Therapeutics, Inc. Stock $otlc

$otlc Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000149315222032950 Filed on November 18, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$348.4K	$593.7K	$1.187M
YoY Change	-64.86%	-49.98%	74.54%
% of Gross Profit
Research & Development	$66.21K	$1.700K	$621.9K
YoY Change	-87.35%	-99.73%	-33.57%
% of Gross Profit
Depreciation & Amortization	$0.00	$0.00	$15.38K
YoY Change	-100.0%	-100.0%	-83.1%
% of Gross Profit
Operating Expenses	$414.6K	$595.4K	$1.809M
YoY Change	-72.63%	-67.08%	11.92%
Operating Profit		-$595.4K	-$1.809M
YoY Change		-67.08%
Interest Expense	-$867.5K	$606.8K	-$299.9K
YoY Change	57.81%	-302.34%	6.55%
% of Operating Profit
Other Income/Expense, Net	$48.83K	-$264.0K	-$46.57K
YoY Change		466.92%
Pretax Income	-$5.344M	-$859.4K	-$1.856M
YoY Change	171.13%	-53.68%	-6.6%
Income Tax
% Of Pretax Income
Net Earnings	-$5.289M	-$777.9K	-$1.563M
YoY Change	194.81%	-50.21%	-21.34%
Net Earnings / Revenue
Basic Earnings Per Share		$0.00	$0.00
Diluted Earnings Per Share	-$0.01	$0.00	-$4.218K
COMMON SHARES
Basic Shares Outstanding	391.1M shares	385.7M shares	370.4M shares
Diluted Shares Outstanding		386.8M shares	370.4M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$241.5K	$253.9K	$78.08K
YoY Change	-57.55%	225.15%	-94.27%
Cash & Equivalents	$241.5K	$253.9K	$98.08K
Short-Term Investments
Other Short-Term Assets	$41.96K	$38.39K	$40.95K
YoY Change	8.2%	-6.25%	-62.09%
Inventory
Prepaid Expenses
Receivables	$19.75K	$19.75K	$69.81K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$303.2K	$312.0K	$188.8K
YoY Change	-51.67%	65.24%	-87.33%
LONG-TERM ASSETS
Property, Plant & Equipment			$2.540K
YoY Change			-86.96%
Goodwill	$12.07M	$16.18M
YoY Change	-42.69%
Intangibles
YoY Change
Long-Term Investments	$22.64M	$22.64M
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$35.81M	$39.92M	$23.00M
YoY Change	55.81%	73.57%	-0.59%
TOTAL ASSETS
Total Short-Term Assets	$303.2K	$312.0K	$188.8K
Total Long-Term Assets	$35.81M	$39.92M	$23.00M
Total Assets	$36.12M	$40.24M	$23.19M
YoY Change	52.95%	73.51%	-5.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.736M	$1.784M	$3.786M
YoY Change	-9.96%	-52.89%	57.14%
Accrued Expenses	$775.1K	$1.069M	$1.047M
YoY Change	-33.47%	2.1%	47.95%
Deferred Revenue
YoY Change
Short-Term Debt	$390.1K	$10.08M	$4.900M
YoY Change	8.57%	105.76%	118.17%
Long-Term Debt Due			$2.050M
YoY Change
Total Short-Term Liabilities	$16.92M	$16.21M	$14.80M
YoY Change	9.5%	9.52%	68.88%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.92M	$16.21M	$14.80M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$16.71M	$16.05M	$15.18M
YoY Change	6.71%	5.73%	55.8%
SHAREHOLDERS EQUITY
Retained Earnings	-$25.93M	-$20.60M
YoY Change	-16.42%
Common Stock	$3.918M	$3.902M
YoY Change	4.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$19.41M	$24.19M	$8.010M
YoY Change
Total Liabilities & Shareholders Equity	$36.12M	$40.24M	$23.19M
YoY Change	52.95%	73.51%	-5.84%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$5.289M	-$777.9K	-$1.563M
YoY Change	194.81%	-50.21%	-21.34%
Depreciation, Depletion And Amortization	$0.00	$0.00	$15.38K
YoY Change	-100.0%	-100.0%	-83.1%
Cash From Operating Activities	-$80.68K	-$206.1K	-$900.7K
YoY Change	-92.44%	-77.12%	-43.11%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	68.25K	60.20K	517.5K
YoY Change	-95.62%	-88.37%	-77.55%
NET CHANGE
Cash From Operating Activities	-80.68K	-206.1K	-900.7K
Cash From Investing Activities
Cash From Financing Activities	68.25K	60.20K	517.5K
Net Change In Cash	-12.43K	-145.9K	-383.2K
YoY Change	-102.53%	-61.93%	-153.13%
FREE CASH FLOW
Cash From Operating Activities	-$80.68K	-$206.1K	-$900.7K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q3	OTLC	Gain On Sale Of Nonfinancial Asset GainOnSaleOfNonfinancialAsset		usd
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 107
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q3	OTLC	Ppp Loan Forgiveness PPPLoanForgiveness		usd
	OTLC	Ppp Loan Forgiveness PPPLoanForgiveness		usd
CY2021Q3	OTLC	Gain On Sale Of Nonfinancial Asset GainOnSaleOfNonfinancialAsset		usd
	OTLC	Gain On Sale Of Nonfinancial Asset GainOnSaleOfNonfinancialAsset		usd
CY2021Q3	OTLC	Reimbursement For Expenses Related Party ReimbursementForExpensesRelatedParty		usd
	OTLC	Reimbursement For Expenses Related Party ReimbursementForExpensesRelatedParty		usd
	dei	Entity Central Index Key EntityCentralIndexKey	0000908259
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet		usd
CY2021Q4	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue		usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2021Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2021Q1	OTLC	Stock Issued During Period Value Conversion Of Preferred Stock StockIssuedDuringPeriodValueConversionOfPreferredStock		usd
	OTLC	Gain On Sale Of Nonfinancial Asset GainOnSaleOfNonfinancialAsset		usd
	OTLC	Common Shares Issued In Lieu Of Restricted Stock Units CommonSharesIssuedInLieuOfRestrictedStockUnits		usd
	us-gaap	Depreciation Depreciation		usd
	OTLC	Proceeds From Payroll Protection Plan ProceedsFromPayrollProtectionPlan		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	OTLC	Common Shares Issued In Lieu Of Services CommonSharesIssuedInLieuOfServices		usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain EquitySecuritiesFvNiUnrealizedGain		usd
	us-gaap	Equity Securities Fv Ni Unrealized Loss EquitySecuritiesFvNiUnrealizedLoss		usd
CY2021Q4	us-gaap	Equity Securities Fv Ni Current And Noncurrent EquitySecuritiesFvNiCurrentAndNoncurrent		usd
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss		usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Purchases FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPurchases		usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Purchases FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPurchases		usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Net FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet		usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-21990
	dei	Entity Registrant Name EntityRegistrantName	Oncotelic Therapeutics, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	13-3679168
	dei	Entity Address Address Line1 EntityAddressAddressLine1	29397 Agoura Road
	dei	Entity Address City Or Town EntityAddressCityOrTown	Agoura Hills
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	91301
	dei	City Area Code CityAreaCode	(650)
	dei	Local Phone Number LocalPhoneNumber	635-7000
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	391107595	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	253882	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15454920	usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	18778	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	312024	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	568769	usd
CY2022Q3	us-gaap	Restricted Cash RestrictedCash	20000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	20000	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	19748	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	19748	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	18394	usd
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000	shares
CY2021Q4	us-gaap	Assets Current AssetsCurrent	627295	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	201180	usd
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000	shares
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	24187011	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	7955673	usd
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	188339	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	821841	usd
CY2022Q3	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	1101760	usd
CY2021Q4	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	1101760	usd
CY2022Q3	us-gaap	Goodwill Goodwill	16182457	usd
CY2021Q4	us-gaap	Goodwill Goodwill	21062455	usd
CY2022Q3	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	22640521	usd
CY2022Q3	us-gaap	Assets Assets	40236762	usd
CY2021Q4	us-gaap	Assets Assets	23613351	usd
CY2022Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2852159	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3092723	usd
CY2022Q3	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	349462	usd
CY2021Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	403423	usd
CY2022Q3	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	2625000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	2625000	usd
CY2022Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	302550	usd
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	340290	usd
CY2022Q3	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	9250021	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	8166622	usd
CY2022Q3	OTLC	Convertible Debt And Short Term Debt Related Party Current ConvertibleDebtAndShortTermDebtRelatedPartyCurrent	831266	usd
CY2021Q4	OTLC	Convertible Debt And Short Term Debt Related Party Current ConvertibleDebtAndShortTermDebtRelatedPartyCurrent	826862	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	16210458	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	390195433	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	390195433	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	375288146	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	375288146	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	3901954	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	3752881	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	40921704	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	35223842	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-20636647	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-31021050	usd
CY2022Q3	us-gaap	Minority Interest MinorityInterest	-160707	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	202758	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	24026304	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8158431	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-257810	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-27504	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	40236762	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	37740	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	239278	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	23613351	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1700	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	621927	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	690705	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3135413	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	593739	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1187035	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4505256	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4475642	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	595439	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	1808962	usd
	us-gaap	Operating Expenses OperatingExpenses	5195961	usd
	us-gaap	Operating Expenses OperatingExpenses	7611055	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-595439	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1808962	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5195961	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7611055	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	606824	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	445363	usd
	us-gaap	Interest Expense InterestExpense	1999164	usd
	us-gaap	Interest Expense InterestExpense	1400249	usd
CY2021Q3	OTLC	Ppp Loan Forgiveness PPPLoanForgiveness	253347	usd
	OTLC	Ppp Loan Forgiveness PPPLoanForgiveness	253347	usd
	OTLC	Gain On Sale Of Nonfinancial Asset GainOnSaleOfNonfinancialAsset	16951477	usd
CY2022Q3	OTLC	Reimbursement For Expenses Related Party ReimbursementForExpensesRelatedParty	-237165	usd
	OTLC	Reimbursement For Expenses Related Party ReimbursementForExpensesRelatedParty	-484657	usd
CY2022Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	105662	usd
CY2021Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	145449	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-263997	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-46567	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	15216900	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-935128	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-859436	usd
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-1855529	usd
	us-gaap	Profit Loss ProfitLoss	10020939	usd
	us-gaap	Profit Loss ProfitLoss	-8546183	usd
CY2022Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-81501	usd
CY2021Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-293001	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-363465	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-949295	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-777935	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	25196	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7596888	usd
CY2022Q2	OTLC	Adjustment Of Additional Paid In Capital Contribution From Shareholder For Payment Of Liabilities AdjustmentOfAdditionalPaidInCapitalContributionFromShareholderForPaymentOfLiabilities	644463	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2022Q2	us-gaap	Profit Loss ProfitLoss	15970695	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	24280110	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1562528	usd
	us-gaap	Net Income Loss NetIncomeLoss	10384404	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	60193	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	241750	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-3568017	usd
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	386751480	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	370443893	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	385610191	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	279358671	shares
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	386751480	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	370443893	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	420738409	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	279358671	shares
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8158431	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	51805	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	297360	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	2905316	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-5090321	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6322591	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	570717	usd
CY2022Q2	OTLC	Adjustments To Additional Paid In Capital Warrant Issuedin Connection With Debt Issuance AdjustmentsToAdditionalPaidInCapitalWarrantIssuedinConnectionWithDebtIssuance	368375	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	46822	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	331251	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	303687	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-859436	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-859436	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	24026304	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	12480833	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	210301	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	605719	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	166575	usd
CY2021Q1	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	620052	usd
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-3122637	usd
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	10960843	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	2023552	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	70000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	99055	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9585433	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	-25000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	23641	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3366602	usd
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	109688	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	226432	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	299890	usd
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-1855529	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8389555	usd
	us-gaap	Profit Loss ProfitLoss	10020939	usd
	us-gaap	Profit Loss ProfitLoss	-8546183	usd
	OTLC	Gain On Sale Of Nonfinancial Asset GainOnSaleOfNonfinancialAsset	16951477	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1560173	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1059525	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	12841	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	38524	usd
	OTLC	Warrants Issued Connection With Private Placement WarrantsIssuedConnectionWithPrivatePlacement	2905316	usd
	OTLC	Warrants Issued Connection With Private Placement WarrantsIssuedConnectionWithPrivatePlacement	2093552	usd
	OTLC	Common Shares Issued In Lieu Of Restricted Stock Units CommonSharesIssuedInLieuOfRestrictedStockUnits	-226432	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	626243	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	299890	usd
	us-gaap	Depreciation Depreciation	7609	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	37740	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	239278	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-257810	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-27504	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-384	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-30865	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	287590	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1600849	usd
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-53961	usd
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	34109	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1371882	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	1613200	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	158820	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	118594	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	983175	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	300000	usd
	us-gaap	Proceeds From Other Short Term Debt ProceedsFromOtherShortTermDebt	500000	usd
	us-gaap	Proceeds From Other Short Term Debt ProceedsFromOtherShortTermDebt	1020875	usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt	500000	usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt	100000	usd
	us-gaap	Repayments Of Other Short Term Debt RepaymentsOfOtherShortTermDebt	60000	usd
	us-gaap	Repayments Of Other Short Term Debt RepaymentsOfOtherShortTermDebt	75000	usd
	OTLC	Proceeds From Payroll Protection Plan ProceedsFromPayrollProtectionPlan	92995	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1056995	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2970664	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-314887	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-395938	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	588769	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	494019	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	273882	usd
CY2022Q3	OTLC	Debentures Notes And Other Debt DebenturesNotesAndOtherDebt	10081287	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	98081	usd
	us-gaap	Interest Paid Net InterestPaidNet	328181	usd
	us-gaap	Interest Paid Net InterestPaidNet	298401	usd
	OTLC	Warrants Issued In Connection With Private Placement WarrantsIssuedInConnectionWithPrivatePlacement	3273691	usd
	OTLC	Warrants Issued In Connection With Private Placement WarrantsIssuedInConnectionWithPrivatePlacement	2190127	usd
	OTLC	Common Shares Issued Upon Partial Conversion Of Debt CommonSharesIssuedUponPartialConversionOfDebt	573001	usd
	OTLC	Common Shares Issued Upon Partial Conversion Of Debt CommonSharesIssuedUponPartialConversionOfDebt	210301	usd
	OTLC	Common Shares Issued In Lieu Of Services CommonSharesIssuedInLieuOfServices	93641	usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	226432	usd
	OTLC	Non Cash Cost Upon Sale Of Common Stock NonCashCostUponSaleOfCommonStock	79180	usd
	OTLC	Non Cash Cost Upon Sale Of Common Stock NonCashCostUponSaleOfCommonStock	39991	usd
	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	570717	usd
	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	605719	usd
	OTLC	Warrants Issuance Cost WarrantsIssuanceCost	2900000	usd
CY2022Q2	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	4025000	shares
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-20600000	usd
CY2022Q3	OTLC	Working Capital Deficit WorkingCapitalDeficit	-15900000	usd
	OTLC	Net Cash Provided By Used In Operations NetCashProvidedByUsedInOperations	1400000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_844_eus-gaap--UseOfEstimates_zOs4qt278Qfl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zIpp6D7uLKI7">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity-based transactions and disclosure of contingent liabilities at the date of the financial statements and revenues and expense during the reporting period. Actual results could materially differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company believes the following critical accounting policies affect its more significant judgments and estimates used in the preparation of the financial statements. Significant estimates include the valuation of goodwill and intangible assets for impairment, deferred tax asset and valuation allowance, and fair value of financial instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	978299	usd
CY2021	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	946424	usd
CY2022Q3	OTLC	Equity Securities Initial Book Value EquitySecuritiesInitialBookValue	22640521	usd
CY2022Q3	us-gaap	Equity Securities Fv Ni Current And Noncurrent EquitySecuritiesFvNiCurrentAndNoncurrent	22640521	usd
	OTLC	Contribution At Cost Basis ContributionAtCostBasis	5689044	usd
	OTLC	Gain On Derecognition Of Nonfinancial Asset Net Of Goodwill And Intangibles GainOnDerecognitionOfNonfinancialAssetNetOfGoodwillAndIntangibles	16951477	usd
CY2022Q3	us-gaap	Equity Securities Fv Ni Current And Noncurrent EquitySecuritiesFvNiCurrentAndNoncurrent	22640521	usd
CY2021Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	340290	usd
CY2020Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	777024	usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Net FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet	-144585	usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Period Increase Decrease FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease	-37740	usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Period Increase Decrease FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease	-239278	usd
CY2022Q3	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	302550	usd
CY2021Q3	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	393161	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	821841	usd
CY2022Q3	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1927749	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1068598	usd
CY2022Q3	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2021	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2022Q3	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	800000	usd
	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	800000	usd
CY2021Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	12841	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	12841	usd
CY2022Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1164974	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	201180	usd
	us-gaap	Variable Interest Entity Ownership Percentage VariableInterestEntityOwnershipPercentage	0.29	pure
CY2021	us-gaap	Variable Interest Entity Ownership Percentage VariableInterestEntityOwnershipPercentage	0.29	pure
CY2022Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2852159	usd
CY2022Q3	OTLC	Finite Lived Intangible Assets Derecognition Upon Transfer Of Asset FiniteLivedIntangibleAssetsDerecognitionUponTransferOfAsset	-809000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1010180	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	188339	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3092723	usd
CY2022Q3	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	349462	usd
CY2021Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	403423	usd
CY2022Q3	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	288966	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zxjOdbHyRQ8f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_zT4VyinmNLSe">Prior Period Reclassifications</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain amounts in prior periods may have been reclassified to conform with current period presentation, if any.</span></p>
CY2022Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1010180	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	38524	usd
CY2022Q3	OTLC	Finite Lived Intangible Assets Derecognition Upon Sale Of Asset FiniteLivedIntangibleAssetsDerecognitionUponSaleOfAsset	800000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1783561	usd
CY2022Q3	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	2401	usd
CY2022Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	291750	usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1250000	usd
CY2022Q3	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-500000	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-1250000	usd
CY2022Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	386734	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	76994	usd
CY2022Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	178484	usd
CY2021Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	76994	usd
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	150000	usd
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	0	usd
CY2022Q3	us-gaap	Interest Payable Current InterestPayableCurrent	30000	usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	10300	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	774600	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	usd
	us-gaap	Conversion Of Stock Description ConversionOfStockDescription	The JVA permits GMP to seek conversion of certain convertible promissory notes entered into between the Company and GMP (see reference to Purchase Agreements and Notes below) into shares of the Common Stock of the Company within 15 business days of the execution of the JVA at a price of $0.2242 per Common Share, the closing price of the Common Share as traded on the OTCQB the day prior to the execution of the JVA, or the closing price of the Common Stock prior to the date of conversion if not within 15 business days of the JVA. Upon the execution of the JVA, Dragon will pay for and hold 55 shares of GMP Bio and the Company will pay for and hold 45 shares of GMP Bio, both to be acquired at $1.00 per share of GMP Bio. Such shares of GMP Bio were issued shortly after the date of the JVA
CY2022Q3	OTLC	Joint Venture Valuation Amount JointVentureValuationAmount	11300000	usd
	OTLC	Licenses Agreement Descripition LicensesAgreementDescripition	The Parties also agreed that if a Rare Pediatric Disease (“RPD”) Priority Review Voucher, upon clinical approval of OT-101 Technologies for treatment of diffuse intrinsic pontine glioma (the “DIPG Voucher”), is issued to GMP Bio and GMP Bio, or a subsidiary thereof, sells the DIPG Voucher to a non-GMP subsidiary, then the Company shall be eligible to receive up to 50% of the net sales proceeds or $50 million, whichever is less. Dragon shall fund the JVA, for a total of approximately $27.7 million, based on the conditions contained in the JVA, and the Company will input the licenses under the Agreements into the JV. The Company is obligated to (i) (A) rectify the chain of legal title such that the Company is the sole legal owner of such rights, (B) complete registration as the sole owner of all the Company’s Patent Rights and (C) provide evidence of such registration that is satisfactory to Dragon; (ii) provide Dragon with copies of official documents issued by the relevant patent offices in the relevant countries evidencing the Company’s legal ownership of all the Company’s Patents Rights; and (iii) reflect the Company’s legal ownership of all the Company’s Patent Rights in the relevant online registers of the relevant patent offices in the relevant countries. The JVA intends to raise funding for the JVA through a Series A round of financing of not less than $20 million.
	OTLC	Private Placement And Financing Disclosure Textblock PrivatePlacementAndFinancingDisclosureTextblock	<p id="xdx_805_ecustom--PrivatePlacementAndFinancingDisclosureTextblock_zdpEgzfzZtA3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 7 - <span id="xdx_82C_zYkUFLH9LQt3">PRIVATE PLACEMENT AND JH DARBIE FINANCING</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the period from July 2020 to March 31, 2021, the Company entered into various subscription agreements with certain accredited investors, including the CEO, pursuant to the JH Darbie Financing, whereby the Company issued and sold a total of <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20200701__20210331__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_z0jh4rsn2svg" title="Sale of transaction shares">100</span> Units, for total gross proceeds of approximately $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn6n6_c20200701__20210331__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_z4eEMowthIQ2" title="Proceeds from private placement">5</span> million, pursuant to the JH Darbie Placement Agreement, with each Unit consisting of:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">■</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200701__20210331__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__dei--LegalEntityAxis__custom--EdgepointAIIncMember_za5eyKi2v3Zf" title="Number of common stock issued">25,000</span> shares of Edge Point Common stock for a price of $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20210331__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__dei--LegalEntityAxis__custom--EdgepointAIIncMember_z5QRJEYbc5Sl" title="Shares issued price per share">1.00</span> per share of Edge Point Common stock.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">■</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One convertible promissory note, convertible up to <span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20200701__20210331__us-gaap--DebtInstrumentAxis__custom--OneConvertiblePromissoryNoteMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__dei--LegalEntityAxis__custom--EdgepointAIIncMember_zAWOpe2xKLs8" title="Number of convertible promissory note converted shares">25,000</span> shares of Edge Point Common stock, at a conversion price of $<span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210331__us-gaap--DebtInstrumentAxis__custom--OneConvertiblePromissoryNoteMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__dei--LegalEntityAxis__custom--EdgepointAIIncMember_zaxk0aVAsm5l" title="Conversion price">1.00</span> per share or up to <span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20200701__20210331__us-gaap--DebtInstrumentAxis__custom--OneConvertiblePromissoryNoteMember__dei--LegalEntityAxis__custom--EdgepointAIIncMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__srt--RangeAxis__srt--MaximumMember_z5nyfaqKclOj" title="Number of convertible promissory note converted shares">138,889</span> shares of the Company’s common stock, at a conversion price of $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210331__us-gaap--DebtInstrumentAxis__custom--OneConvertiblePromissoryNoteMember__dei--LegalEntityAxis__custom--EdgepointAIIncMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__srt--RangeAxis__srt--MaximumMember_zdSvrQ53uIV5" title="Conversion price">0.18</span> per share.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">■</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--EdgepointAIIncMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember_z6RHeAVL2UJi" title="Warrants to purchase common stock">50,000</span> warrants to purchase an equivalent number of shares of Edge Point Common stock at $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--EdgepointAIIncMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember_zGTdx9q8R2f2" title="Warrants exercise price">1.00</span> per share and an equivalent number of shares of the Company’s common stock at $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--EdgepointAIIncMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember_zKFEZS1oy598" title="Shares issued price per share">0.20</span> per share with a <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--EdgepointAIIncMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember_zCy3MOuac7Vi" title="Warrant term::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl1380">three</span></span>-year expiration date. Either the Edgepoint or the Company’s warrants would be exercised.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company incurred approximately $<span id="xdx_90E_eus-gaap--DeferredFinanceCostsNet_iI_pn4n6_c20210331__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember_zQYWevazToe" title="Issuance costs">0.64</span> million of issuance costs, including legal costs of approximately $<span id="xdx_90D_eus-gaap--LegalFees_pp0p0_c20200701__20210331__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember_z1TUAFsTeHx9" title="Legal costs">39,000</span>, that are incremental costs directly related to the issuance of the various instruments bundled in the offering.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrently with the sale of the Units, JH Darbie was granted a warrant, exercisable over a five-year period, to purchase <span id="xdx_90A_ecustom--PercentageOfUnitsGranted_pid_dp_uPure_c20200701__20210331__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember_zqOtQd9W2fc7" title="Percentage of units granted">10</span>% of the number of Units sold in the JH Darbie Financing. As such, the Company granted <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20200701__20210331__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember_z5G8c9TJgYCl">10</span> Units to JH Darbie pursuant to the JH Darbie Placement Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The terms of convertible notes are summarized as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">■</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term: Through March 31, 2022, extended further to March 31, 2023</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">■</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Coupon: <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20200701__20210331__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember_zm6bi5Buu9i6" title="Interest rate">16</span>%.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">■</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible at the option of the holder at any time in the Company’s Common Stock or Edgepoint Common Stock.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">■</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The conversion price is initially set at $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210331__dei--LegalEntityAxis__custom--EdgepointAIIncMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__srt--RangeAxis__srt--MaximumMember_zPuYFoGKMMF3" title="Conversion price">0.18</span> per share for the Company’s Common Stock or $<span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210331__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__dei--LegalEntityAxis__custom--EdgepointAIIncMember_zoSLZcGNuwSb" title="Conversion price">1.00</span> for Edgepoint Common Stock, subject to adjustment.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company allocated the proceeds among the freestanding financial instruments that were issued in the single transaction using the relative fair value method, which affects the determination of each financial instrument initial carrying amount. The Company utilized the relative fair value method as none of the freestanding financial instruments issued as part of the single transaction are measured at fair value. Under the relative fair value method, the Company made separate estimates of the fair value of each freestanding financial instrument and then allocated the proceeds in proportion to those fair value amounts. The Company recorded non-controlling interests of approximately $<span id="xdx_90D_eus-gaap--MinorityInterest_iI_pn6n6_c20210331__dei--LegalEntityAxis__custom--EdgepointAIIncMember_zuOkzguy65w7" title="Non-controlling interests">1</span> million in Edgepoint. Non-controlling interests represent the portion of net assets in consolidated entities that are not owned by the Company and are reported as a component of equity in the consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of the multiple closings of the Company during the six months ended June 30, 2021, under the private placement memorandum with JH Darbie, the estimated volume weighted grant date fair value of approximately $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__dei--LegalEntityAxis__custom--JHDarbieAndCoIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1sAJyAG42fi">0.21</span> per share associated with the warrants to purchase up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20210630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__dei--LegalEntityAxis__custom--JHDarbieAndCoIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7ZnpQlWoa38">2,035,000</span> shares of common stock issued in this offering, or a total of approximately $ <span id="xdx_900_eus-gaap--AdjustmentsToAdditionalPaidInCapitalMarkToMarket_pn5n6_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__dei--LegalEntityAxis__custom--JHDarbieAndCoIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zT0owp2rIk5a" title="Aadditional paid-in capital on relative fair value">0.7</span> million, was recorded to additional paid-in capital on a relative fair value basis. All warrants sold in this offering had an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210630__dei--LegalEntityAxis__custom--JHDarbieAndCoIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zN8VXJx8x0dd" title="Warrants exercise price">0.20</span> per share of the Company stock or $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210630__dei--LegalEntityAxis__custom--EdgepointAIIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPxVE2Y2Htpf" title="Warrants exercise price">1.00</span> per share of Edge Point, subject to adjustment, are exercisable immediately and expire <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20210630__dei--LegalEntityAxis__custom--JHDarbieAndCoIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhvqrEFUuDqk" title="Warrant term">three years</span> from the date of issuance. The fair value of the warrants was estimated using a Black Scholes valuation models using the following input values:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_gL3FVAALMORAN-HOFU_zrOe8Yo8KAV8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zOp3CjrYKNzi" style="display: none">SCHEDULE OF FAIR VALUE WARRANTS ESTIMATED USING BLACK SCHOLES VALUATION MODEL</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected Term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z2HdXwu1aPn2" title="Expected Term">1.5</span> years</span></td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zp3pYWRRMGU5" title="Fair value of warrant measurement percentage">152.3</span>%-<span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zwQ94tMgGdXh" title="Fair value of warrant measurement percentage">164.8</span></span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rates</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zGA9r9ljKhGc" title="Fair value of warrant measurement percentage">0.09</span>%-<span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zQO49wVqedQk" title="Fair value of warrant measurement percentage">0.11</span></span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 80%; text-align: left">Dividend yields</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z1330RNYpaB6" title="Fair value of warrant measurement percentage">0.00</span></td> <td style="width: 1%; text-align: right">%</td></tr> </table> <p id="xdx_8A9_zrG1JLaAoBV5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In February 2022, the Company and all except one of the Investors agreed to extend the maturity date of the Notes from March 31, 2022, to March 31, 2023. In consideration for the extension of the Notes, the Company issued to the Investors an aggregate of <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220228__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zII2wD2168uj" title="Warrants to purchase common stock">33,000,066</span> Oncotelic Warrants at a price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220228__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zwlSYgY2KN97">0.15</span> per share of Company’s Common Stock and are immediately exercisable and expire <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20220228__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_ziC3DIOQZg2b" title="Warrant term">two years</span> from the date of issuance or <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220228__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zikgG69XzjRb" title="Warrant maturity date">February 9, 2024</span>. <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20220201__20220228__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zvJ8JQ6RkTIa" title="Warrants to purchase common stock, description">Each Investor will be entitled to receive 333,334 Oncotelic Warrants for each Unit purchased. Upon the amendment of the terms of the convertible notes under the private placement memorandum. As incentive to extend the maturity date, approximately 33 million warrants were issued to the Unit Holders who participated in the amendment, The Company repaid the 1-unit holder who did not participate in the amendment shortly after March 31, 2022</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company reviewed the guidance per ASC 470-60 Troubled debt restructurings and ASC 470-50 Debt-Modifications and Extinguishments and concluded that the terms of the agreements were substantially different as of June 30, 2022, and, accounted for the transaction as a debt extinguishment. The loss is recognized equal to the difference between the net carrying amount of the original debt and the fair value of the modified debt instrument.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">At March 31, 2022, the Company estimated the fair value of the warrants issued in conjunction with the amendment of the private placement under the JH Darbie financing based on assumptions used in the Black-Scholes valuation model. The warrants resulted in an aggregate fair value of approximately $<span id="xdx_907_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20220301__20220331__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_z4ecLeAa6LWl" title="Fair value adjustment of warrants">2.9</span> million. The key valuation assumptions used consists, in part, of the price of the Company’s Common Stock, a risk-free interest rate based on the yield of a Treasury note and expected volatility of the Company’s Common Stock all as of the measurement date. The Company used the following assumptions to estimate fair value of the warrants:</span></p> <div id="xdx_C0C_gL3FVAALMORAN-HOFU_zyCjT22GnwV1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 27pt"><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" id="xdx_308_134_zci63v1nEHe2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - SCHEDULE OF FAIR VALUE WARRANTS ESTIMATED USING BLACK SCHOLES VALUATION MODEL (Details)"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">Strike price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="text-align: right; width: 16%">$<span id="xdx_902_eus-gaap--SharePrice_iI_pid_c20220331_zWtywHgLHeOa" title="Strike price">0.15</span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected Term</td><td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zNAFEk1QTeHj" title="Expected Term">1</span> year</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected volatility</td><td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zkNxHVL5OQzj" title="Fair value of warrant measurement percentage">115.1</span></td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Risk-free interest rates</td><td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z5GKfoI1Bek8" title="Fair value of warrant measurement percentage">1.36</span></td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Dividend yields</td><td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zjLke307RTjf" title="Fair value of warrant measurement percentage">0.00</span></td> <td>%</td></tr> </table> </div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C0C_gL3FVAALMORAN-HOFU_zItNjfGPFP7c"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized amortization expense related to the debt discount and debt issuance costs of approximately $<span id="xdx_907_eus-gaap--AmortizationOfDebtDiscountPremium_pn3n3_c20220101__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--InterestExpenseMember_zuNUk7jPyRmb" title="Amortization of debt discount and debt issuance costs">71 thousand</span> and approximately $<span id="xdx_90F_eus-gaap--AmortizationOfDebtDiscountPremium_pn5n6_c20210101__20210930__us-gaap--IncomeStatementLocationAxis__us-gaap--InterestExpenseMember_zDcYJP3xeTq7" title="Amortization of debt discount and debt issuance costs">0.9 million</span> for the nine months ended September 30, 2022 and 2021 respectively, which is included in interest expense in the statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q1	us-gaap	Share Price SharePrice	0.15
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	16592620	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.30
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	2359	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	11.88
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	9100000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.10
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	25690261	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.23
CY2022Q3	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	25690261	shares
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P8Y3M18D
CY2022Q3	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	0.30
CY2022Q3	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	15497761	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.07
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	300000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	600000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	300000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	300000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	53314424	shares
CY2021Q4	OTLC	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	0.20
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	38623816	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	9615385	shares
	OTLC	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0.13
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	82322855	shares
CY2022Q3	OTLC	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	0.18
CY2022Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	82322855	shares
CY2022Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P1Y
CY2022Q3	OTLC	Class Of Warrant Weighted Average Exercise Price Of Warrants ClassOfWarrantWeightedAverageExercisePriceOfWarrants	0.18
CY2022Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	82322855	shares
	OTLC	Operating Loss Carryforwards Expiration Year OperatingLossCarryforwardsExpirationYear	Portions of these carry forwards will expire through 2038

Files In Submission

Name	View Source	Status
0001493152-22-032950-index-headers.html	Edgar Link	pending
0001493152-22-032950-index.html	Edgar Link	pending
0001493152-22-032950.txt	Edgar Link	pending
0001493152-22-032950-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
otlc-20220930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
otlc-20220930_cal.xml	Edgar Link	unprocessable
otlc-20220930_def.xml	Edgar Link	unprocessable
otlc-20220930_lab.xml	Edgar Link	unprocessable
otlc-20220930_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OTLC
Oncotelic Therapeutics, Inc. Stock $otlc

2022 Q4 Form 10-Q Financial Statement

#000149315222032950 Filed on November 18, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OTLC Oncotelic Therapeutics, Inc. Stock $otlc

2022 Q4 Form 10-Q Financial Statement

#000149315222032950 Filed on November 18, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OTLC
Oncotelic Therapeutics, Inc. Stock $otlc